DDInter1646 DDInter1658
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Saxagliptin {u} (Compound) resembles {v} (Compound) Vildagliptin
Saxagliptin {u} (Compound) binds {v} (Gene) DPP8
Saxagliptin {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Saxagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Saxagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midostaurin
Saxagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroflumethiazide
Saxagliptin {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Saxagliptin (Compound) resembles Vildagliptin (Compound)
Saxagliptin (Compound) binds DPP8 (Gene)
Saxagliptin (Compound) causes Upper respiratory tract infection (Side Effect)
Saxagliptin may cause a minor interaction that can limit clinical effects when taken with Modafinil
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Saxagliptin may lead to a major life threatening interaction when taken with Bexarotene